Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

被引：0

作者：

Mara Persano

Margherita Rimini

Toshifumi Tada

Goki Suda

Shigeo Shimose

Masatoshi Kudo

Jaekyung Cheon

Fabian Finkelmeier

Ho Yeong Lim

Lorenza Rimassa

José Presa

Gianluca Masi

Changhoon Yoo

Sara Lonardi

Francesco Tovoli

Takashi Kumada

Naoya Sakamoto

Hideki Iwamoto

Tomoko Aoki

Hong Jae Chon

Vera Himmelsbach

Tiziana Pressiani

Takumi Kawaguchi

Margarida Montes

Caterina Vivaldi

Caterina Soldà

Fabio Piscaglia

Atsushi Hiraoka

Takuya Sho

Takashi Niizeki

Naoshi Nishida

Christoph Steup

Massimo Iavarone

Giovanni Di Costanzo

Fabio Marra

Mario Scartozzi

Emiliano Tamburini

Giuseppe Cabibbo

Francesco Giuseppe Foschi

Marianna Silletta

Masashi Hirooka

Kazuya Kariyama

Joji Tani

Masanori Atsukawa

Koichi Takaguchi

Ei Itobayashi

Shinya Fukunishi

Kunihiko Tsuji

Toru Ishikawa

Kazuto Tajiri

机构：

[1] University Hospital of Cagliari,Medical Oncology

[2] IRCCS San Raffaele Hospital,Department of Medical Oncology

[3] Japanese Red Cross Himeji Hospital,Department of Internal Medicine

[4] Hokkaido University,Department of Gastroenterology and Hepatology, Graduate School of Medicine

[5] Kurume University School of Medicine,Division of Gastroenterology, Department of Medicine

[6] Kindai University Faculty of Medicine,Department of Gastroenterology and Hepatology

[7] CHA University School of Medicine,Department of Medical Oncology, CHA Bundang Medical Center

[8] University Hospital Frankfurt,Department of Internal Medicine 1

[9] Goethe University,Department of Medicine, Samsung Medical Center, School of Medicine

[10] Sungkyunkwan University,Department of Biomedical Sciences

[11] Humanitas University,Unit of Medical Oncology 2

[12] Humanitas Cancer Center,Department of Translational Research and New Technologies in Medicine and Surgery

[13] IRCCS Humanitas Research Hospital,Department of Oncology, ASAN Medical Center

[14] Liver Unit-CHTMAD,Oncology Unit 1

[15] University Hospital of Pisa,Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases

[16] University of Pisa,Department of Nursing

[17] University of Ulsan College of Medicine,Gastroenterology Center

[18] Veneto Institute of Oncology IOV-IRCCS,Division of Gastroenterology and Hepatology

[19] IRCCS Azienda Ospedaliero-Universitaria di Bologna,Dipartimento di Medicina Sperimentale e Clinica

[20] Gifu Kyoritsu University,Department of Oncology and Palliative Care, Cardinale G Panico

[21] Ehime Prefectural Central Hospital,Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE

[22] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano,Department of Internal Medicine

[23] Department of Hepatology,Division of Medical Oncology

[24] Università di Firenze,Department of Gastroenterology and Metabology

[25] Tricase City Hospital,Department of Gastroenterology

[26] University of Palermo,Department of Gastroenterology and Hepatology

[27] Ospedale per gli Infermi di Faenza,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[28] Policlinico Universitario Campus Bio-Medico,Department of Hepatology

[29] Ehime University Graduate School of Medicine,Department of Gastroenterology

[30] Okayama City Hospital,Department of Gastroenterology

[31] Kagawa University,Center of Gastroenterology

[32] Nippon Medical School,Department of Gastroenterology

[33] Kagawa Prefectural Central Hospital,Department of Gastroenterology

[34] Asahi General Hospital,Hepato

[35] Osaka Medical and Pharmaceutical University,biliary Center

[36] Teine Keijinkai Hospital,Department of Gastroenterology and Hepatology

[37] Saiseikai Niigata Hospital,Department of Gastroenterology

[38] Toyama University Hospital,Division of Gastroenterology and Hepatology, Department of Internal medicine

[39] Japanese Red Cross Matsuyama Hospital,Department of Gastroenterology

[40] Ogaki Municipal Hospital,Department of Clinical Research

[41] Japanese Red Cross Takamatsu Hospital,Division of Gastroenterology and Hepatology

[42] Hyogo Medical University,Department of Hepatology

[43] Gunma Saiseikai Maebashi Hospital,Department of Surgery

[44] National Hospital Organization Takasaki General Medical Center,Department of Gastroenterology

[45] Otakanomori Hospital,Drug Development Unit

[46] Hamamatsu University School of Medicine,Department of Oncology

[47] Kansai Medical University,undefined

[48] National Hospital Organization Takasaki General Medical Center,undefined

[49] Sarah Cannon Research Institute UK,undefined

[50] IRCCS San Raffaele Scientific Institute Hospital,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷

关键词：

Advanced HCC; Atezolizumab plus bevacizumab; First-line therapy; Lenvatinib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：5591 / 5602

页数：11

共 50 条

[31] Multicenter, real-world experience with lenvatinib for patients with advanced hepatocellular carcinoma in Japan
Sho, Takuya
Suda, Goki
Ogawa, Koji
Nakai, Masato
Morikawa, Kenichi
Sakamoto., Naoya
JOURNAL OF HEPATOLOGY, 2020, 73 : S909 - S909
[32] Real-world experience of atezolizumab plus bevacizumab combination treatment in high risk patients with advanced hepatocellular carcinoma
Hwang, Sangyoun
Woo, Hyun Young
Heo, Jeong
Kim, Hyung Jun
Park, Young Joo
Yi, Kiyoun
Lee, Yu Rim
Park, Soo Young
Jang, Byoung Kuk
Chung, Woo Jin
Tak, Won Young
JOURNAL OF HEPATOLOGY, 2023, 78 : S588 - S588
[33] Letter to the editor on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study"
Wu, Meng-Che
Chang, Hui-Chin
Jhang, Yi-Sheng
Gau, Shuo-Yan
CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
[34] Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study
Welland, Sabrina
Leyh, Catherine
Finkelmeier, Fabian
Jefremow, Andre
Shmanko, Kateryna
Gonzalez-Carmona, Maria A.
Kandulski, Arne
Jeliazkova, Petia
Best, Jan
Fruendt, Thorben W.
Djanani, Angela
Pangerl, Maria
Maieron, Andreas
Greil, Richard
Fricke, Christina
Sookthai, Disorn
Guenther, Rainer
Schmiderer, Andreas
Wege, Henning
Venerito, Marino
Ehmer, Ursula
Mueller, Martina
Strassburg, Christian P.
Weinmann, Arndt
Siebler, Jurgen
Waidmann, Oliver
Lange, Christian M.
Saborowski, Anna
Vogel, Arndt
LIVER CANCER, 2022, 11 (03) : 219 - 232
[35] Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study
Kurvi Patwala
David Stephen Prince
Yael Celermajer
Waafiqa Alam
Eldho Paul
Simone Irene Strasser
Geoffrey William McCaughan
Paul Gow
Siddharth Sood
Elise Murphy
Stuart Roberts
Elliot Freeman
Elizabeth Stratton
Scott Anthony Davison
Miriam Tania Levy
McCawley Clark-Dickson
Vi Nguyen
Sally Bell
Amanda Nicoll
Ashley Bloom
Alice Unah Lee
Marno Ryan
Jessica Howell
Zina Valaydon
Alexandra Mack
Ken Liu
Anouk Dev
Hepatology International, 2022, 16 : 1170 - 1178
[36] Atezolizumab and bevacizumab in advanced hepatocellular carcinoma: Real-world data.
Bezalel, Nomi
Davidov, Yana
Likhter, Mariya
Ezra, Oranit Cohen
Inbar, Yael
Halpern, Naama
Ben Boursi
Beller, Tamar
Pery, Ron
Shmueli, Einat S.
Nachmany, Ido
Ben Ari, Ziv
Margalit, Ofer
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
Yano, Shigeki
Kawaoka, Tomokazu
Johira, Yusuke
Miura, Ryoichi
Kosaka, Masanari
Shirane, Yuki
Murakami, Serami
Amioka, Kei
Naruto, Kensuke
Ando, Yuwa
Kosaka, Yumi
Yamaoka, Kenji
Kodama, Kenichiro
Uchikawa, Shinsuke
Fujino, Hatsue
Ohno, Atsushi
Nakahara, Takashi
Murakami, Eisuke
Okamoto, Wataru
Yamauchi, Masami
Imamura, Michio
Mori, Keiichi
Arihiro, Kouji
Kuroda, Shintaro
Kobayashi, Tsuyoshi
Ohdan, Hideki
Aikata, Hiroshi
MEDICINE, 2021, 100 (42) : E27576
[38] Risk of bleeding and thromboembolic events with atezolizumab/bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter, retrospective study
Ben Khaled, Najib
Moeller, Marie
Jochheim, Leonie
Leyh, Catherine
Ehmer, Ursula
Boettcher, Katrin
Leicht, Hans Benno
Rau, Monika
Sinner, Friedrich
Venerito, Marino
Gairing, Simon Johannes
Foerster, Friedrich
de Toni, Enrico
Geier, Andreas
Reiter, Florian P.
JOURNAL OF HEPATOLOGY, 2023, 78 : S51 - S51
[39] Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma
Komatsu, Shohei
Yano, Yoshihiko
Kido, Masahiro
Kuramitsu, Kaori
Gon, Hidetoshi
Fukushima, Kenji
Urade, Takeshi
So, Shinichi
Yamamoto, Atsushi
Goto, Tadahiro
Yanagimoto, Hiroaki
Toyama, Hirochika
Ueda, Yoshihide
Kodama, Yuzo
Fukumoto, Takumi
ANTICANCER RESEARCH, 2022, 42 (11) : 5479 - 5486
[40] Concurrent transarterial chemoembolization plus atezolizumab and bevacizumab in unresectable hepatocellular carcinoma: Interim analysis from a multicenter real-world study (CHANCE 023).
Zhu, Haidong
Lu, Jian
Teng, Gao-Jun
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 542 - 542

← 1 2 3 4 5 →